News Press Releases

26 Stocks Moving In Tuesday's Pre-Market Session

ADMA, AMKR, CHGG, COTY, EA, ESPR, FRO, GEVO, GILD, KMDA, NMFC, PMT, SBS | February 12, 2019

Gainers

SCWorx Corp. (NASDAQ: WORX) rose 44.4 percent to $7.15 in pre-market trading after climbing 19.19 percent on Monday.
Coty Inc. (NYSE: COTY) shares rose 18.1 percent to $11.41 in pre-market trading after JAB proposed a partial tender offer to acquire additional shares at $11.65 per share in cash.
Pyxus International, Inc. (NYSE: PYX) rose 14.8 percent to $19.92 in pre-market trading after reporting Q3 results.
Frontline Ltd. (NYSE: FRO) shares rose 12.1 percent to $5.64 in pre-market trading after gaining 2.65 percent on Monday.
Mimecast Limited (NASDAQ: MIME) shares rose 10.8 percent to $47.45 in pre-market trading after reporting upbeat Q3 results. The company also issued Q4 sales guidance above analyst estimates.
Chegg, Inc. (NYSE: CHGG) rose 10 percent to $38.28 in pre-market trading after the company reported better-than-expected fourth-quarter results and issued strong first-quarter and FY2019 sales guidance.
ADMA Biologics, Inc. (NASDAQ: ADMA) rose 8 percent to $3.11 in pre-market trading after the company disclosed that it has entered into a $72.5 million loan facility with Perceptive Advisors.
Kamada Ltd. (NASDAQ: KMDA) rose 7.7 percent to $5.86 in pre-market trading after reporting upbeat Q4 results.
Electronic Arts Inc. (NASDAQ: EA) rose 7.4 percent to $104.45 in pre-market trading amid the success of its 'Apex Legends' battle royale game. Apex Legends achieved 25 million players over past week.
Gevo, Inc. (NASDAQ: GEVO) shares rose 7.4 percent to $2.47 in pre-market trading after climbing 2.22 percent on Monday.
Viking Therapeutics, Inc. (NASDAQ: VKTX) rose 7.2 percent to $8.69 in pre-market trading.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) rose 7.1 percent to $47.91 in pre-market trading.
Adaptimmune Therapeutics plc (NASDAQ: ADAP) rose 6.8 percent to $5.50 in pre-market trading after gaining 3.21 percent on Monday.
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) rose 6.1 percent to $123.16 in pre-market trading.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Check out these big penny stock gainers and losers

Losers

Varonis Systems, Inc. (NASDAQ: VRNS) shares fell 23.4 percent to $49.00 in pre-market trading after the company issued weak guidance.
Bristow Group Inc. (NYSE: BRS) fell 16.7 percent to $2.55 in pre-market trading. Bristow and Columbia Helicopters terminated proposed transaction for Bristow to acquire Columbia. Bristow Group posted Q3 loss of $0.57 per share on sales of $317.09 million.
Veeco Instruments Inc. (NASDAQ: VECO) fell 15.4 percent to $9.30 in pre-market trading following Q4 results.
Companhia de Saneamento Bsc DEDSP (NYSE: SBS) fell 6.8 percent to $9.52 in pre-market trading after dropping 8.35 percent on Monday.
Molson Coors Brewing Company (NYSE: TAP) fell 6.7 percent to $61.00 in pre-market trading following weak Q4 sales. The company also announced plans to restate its 2016 and 2017 financial statements.
Livent Corporation (NYSE: LTHM) fell 4.7 percent to $12.50 in pre-market trading after the company reported downbeat Q4 results and issued weak Q1 forecast.
Amkor Technology, Inc. (NASDAQ: AMKR) fell 4.5 percent to $8.10 in pre-market trading. Amkor reported upbeat results for its fourth quarter, but issued weak first-quarter earnings and sales guidance.
Shopify Inc. (NYSE: SHOP) fell 4.4 percent to $165.6 in pre-market trading after reporting a Q4 loss.
22nd Century Group, Inc. (NASDAQ: XXII) fell 3.3 percent to $2.37 in pre-market trading.
New Mountain Finance Corporation (NYSE: NMFC) shares fell 3 percent to $13.47 in pre-market. New Mountain Finance priced its 3.75 million share common stock offering at $13.57 per share.
PennyMac Mortgage Investment Trust (NYSE: PMT) fell 2.8 percent to $20.72 in pre-market trading after reporting a 7 million share common stock offering.
Gilead Sciences, Inc. (NASDAQ: GILD) fell 3.2 percent to $65.49 in pre-market trading after reporting that topline data from phase 3 STELLAR-4 study of Selonsertib in compensated Cirrhosis due to NASH did not meet its primary endpoint.